Advertise on podcast: NEI Podcast

Originally released in 2022, this episode of The PsychopharmaStahlogy Show features Drs. Andrew Cutler and Stephen Stahl in conversation with Dr. Tiffany Greenwood on the genetic and trait-based links between bipolar disorder and creativity. They explore how temperament, personality, and cognitive style may occupy the space between madness and genius, the role of dopamine, evolutionary explanations for why bipolar risk persists, and why stabilizing mood doesn't have to mean losing creativity.   Tiffany A. Greenwood, PhD, is an Associate Professor in the Department of Psychiatry at the University of California San Diego. Her research uses dimensional traits to refine the genetic signal in bipolar disorder and schizophrenia, through collaborations including the Bipolar Genome Study, the Consortium on the Genetics of Schizophrenia, and the Psychiatric Genomics Consortium. She also studies bipolar disorder as an extreme of normal variation in temperament, personality, cognition, and creativity.  Stephen M. Stahl, MD, PhD, DSc (Hon.), is a psychiatrist, psychopharmacologist, and internationally recognized educator in clinical neuroscience and psychopharmacology. He is the author of widely used educational resources, including Stahl's Essential Psychopharmacology and Stahl's Prescriber's Guide, and his work focuses on translating complex neurobiology and treatment mechanisms into practical clinical concepts for mental health clinicians.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Resources  Greenwood TA, Chow LJ, Gur RC, Kelsoe JR. Bipolar spectrum traits and the space between Madness and Genius: The Muse is in the Dose. J Psychiatr Res, 2022;153:149-158. doi:10.1016/j.jpsychires.2022.07.009  Greenwood TA. Creativity and Bipolar Disorder: A Shared Genetic Vulnerability. Annu Rev Clin Psychol. 2020;16:239-264. doi:10.1146/annurev-clinpsy-050718-095449  Greenwood TA. Positive Traits in the Bipolar Spectrum: The Space between Madness and Genius. Mol Neuropsychiatry. 2017;2(4):198-212. doi:10.1159/000452416  Fall Congress  Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!  Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

Originally released in 2024, this episode features the late Dr. Vladimir Maletic in conversation with Drs. Andy Cutler and Stephen Stahl about the clinical significance and neurobiology of anhedonia. They discuss its different dimensions, how it differs from emotional blunting, its relationship to functioning and treatment response, and practical approaches to assessment and treatment. The episode highlights why recovery from depression requires restoring interest, motivation, and pleasure—not simply reducing negative symptoms.  Vladimir Maletic, MD, MS, was a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in Greenville and a consulting associate in the Division of Child and Adolescent Psychiatry at Duke University. Board certified in psychiatry and neurology, his areas of expertise included the neurobiology of mood disorders, schizophrenia, pain, and sleep–wake regulation.  Stephen M. Stahl, MD, PhD, DSc (Hon.), is a psychiatrist, psychopharmacologist, and internationally recognized educator in clinical neuroscience and psychopharmacology. He is the author of widely used educational resources, including Stahl's Essential Psychopharmacology and Stahl's Prescriber's Guide, and his work focuses on translating complex neurobiology and treatment mechanisms into practical clinical concepts for mental health clinicians.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress  Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!  Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler speaks with Dr. Tim Wilens about the complex relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders. They discuss how to distinguish ADHD from substance-related cognitive symptoms, determine when co-occurring conditions should be treated concurrently, and select appropriate ADHD medications based on the substance involved. Dr. Wilens also examines stimulant misuse and diversion, the role of nonstimulants, what is known about centanafadine's abuse potential, and practical approaches to monitoring treatment without undermining the therapeutic relationship.  Timothy E. Wilens, MD, is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens' research interests include the relationship among ADHD, bipolar disorder, and substance use disorders, embedded health care models, and the pharmacotherapy of ADHD across the lifespan.     Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

Originally released in 2021, this episode features Dr. Thomas Schwartz discussing common mistakes in psychopharmacology and how psychiatric clinicians can recognize and manage them. He explores diagnostic uncertainty, medication dosing, informed consent and monitoring, and rational versus irrational polypharmacy. He also considers how clinicians can reassess inherited diagnoses, learn from prescribing errors, and preserve the therapeutic relationship when mistakes occur.   Thomas L. Schwartz, MD, is a Distinguished Teaching Professor at Norton College of Medicine, SUNY Upstate Medical University in Syracuse, New York. He is an award-winning educator deeply involved in medical student and resident training, as well as the development of continuing medical education in psychiatry.  Fall Congress  Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!  Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode of PsychopharmaPearls, Dr. Andy Cutler and Dr. Will Sauvé discuss what clinicians need to know about kratom. They review why patients use it, signs of misuse, dependence, or withdrawal, and key pharmacologic and safety concerns. The conversation also offers practical guidance for discussing kratom use and incorporating it into treatment planning.  William Sauvé, MD, is a board-certified psychiatrist and Chief Medical Officer at Osmind. He has extensive experience in interventional psychiatry, including TMS and esketamine, and previously served for 11 years as an active-duty Navy psychiatrist. He also serves on the faculty of the Neuroscience Education Institute.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress  Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  X: https://nei.global/twitter  Instagram: https://nei.global/instagram  Facebook: https://nei.global/facebook  LinkedIn: https://nei.global/linkedin

In this episode, Dr. Andy Cutler is joined by Drs. Stephen Stahl and Jeffrey Strawn to discuss deprescribing practices in psychiatry. They explore why deprescribing is an essential clinical skill, how to determine whether a patient still needs a medication, dose, or combination, and how to approach tapering in a way that balances relapse prevention, withdrawal risk, and patient-centered care. The conversation also covers practical considerations for deprescribing antidepressants, antipsychotics, benzodiazepines, and sedative-hypnotics, with attention to common pitfalls and strategies for safer, more intentional medication management.  Stephen M. Stahl, MD, PhD, DSc (Hon.), is a psychiatrist, psychopharmacologist, and internationally recognized educator in clinical neuroscience and psychopharmacology. He is the author of widely used educational resources including Stahl's Essential Psychopharmacology, Stahl's Prescriber's Guide, and Stahl's Deprescriber's Guide, and his work focuses on translating complex neurobiology into practical clinical concepts for mental health clinicians.  Jeffrey R. Strawn, MD, FAACAP, is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati, Ohio. He is Director of the UC Anxiety Disorders Research Program and Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC, and he is the author of Stahl's Deprescriber's Guide.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Strawn, JR, Stahl SM. Stahl's Deprescriber's Guide. Cambridge University Press; 2026. https://doi.org/10.1017/9781009642187  Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler is joined by Dr. Roger McIntyre to discuss GLP-1 receptor agonists in psychiatry and why these medications may be relevant beyond weight loss. They explore the emerging role of GLP-1s in metabolic psychiatry, including potential connections with mood disorders, cognition, reward pathways, cardiometabolic health, and psychiatric medication-associated weight gain. Dr. McIntyre also discusses what psychiatric providers should know now, where the evidence is still evolving, and what future research is needed before GLP-1 or incretin-based therapies could be considered part of psychiatric treatment.  Roger S. McIntyre, MD, FRCPC, is Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto. He is an internationally recognized expert in mood disorders and psychopharmacology, with published scholarship and presentations exploring the relevance of GLP-1 receptor agonists to psychiatry.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

Originally released in June 2023, this episode features Dr. Cynthia Bulik in a discussion of eating disorders, nutrition, and the brain. The conversation explores anorexia nervosa, bulimia nervosa, binge eating disorder, ARFID, common misconceptions about eating disorders, and the evolving understanding of how biology, genetics, and environment shape risk, diagnosis, and recovery.   Cynthia Bulik, PhD, FAED, is a Distinguished Professor of Eating Disorders in the Department of Psychiatry at the University of North Carolina at Chapel Hill and Professor of Nutrition in the Gillings School of Global Public Health. She is the founding director of the UNC Center of Excellence for Eating Disorders and directs the Centre for Eating Disorders Innovation at Karolinska Institutet, with research focused on the biology, genetics, prevention, and treatment of eating disorders.  Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership  As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler talks with Dr. Bhagwan Bahroo about nutritional interventions in psychiatry, including diet, supplements, metabolic health, inflammation, and the gut-brain axis. They explore where the evidence is strongest, where hype outpaces the data, and how clinicians can discuss nutritional strategies as adjunctive tools without losing focus on core treatments.  Bhagwan A. Bahroo, MD, DLFAPA, is a board-certified psychiatrist in adult, addiction, and forensic psychiatry and an Assistant Professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has extensive clinical experience at Walter Reed National Military Medical Center and has worked in interventional psychiatry, including TMS and esketamine, with an interest in nutrition and its role in mental health.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode of PsychopharmaPearls, Dr. Andy Cutler talks with Dr. Leslie Citrome about akathisia, a common but often misdiagnosed antipsychotic side effect that can look like agitation, anxiety, irritability, or worsening psychiatric symptoms. They discuss how to recognize akathisia in clinical practice, distinguish it from true agitation, identify key timing and symptom clues, and avoid common treatment mistakes, including why benztropine is not an appropriate treatment for akathisia.  Leslie Citrome, MD, MPH, is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College and an internationally recognized expert in psychopharmacology and clinical trial interpretation. He has authored more than 600 scientific publications and frequently lectures on applying research findings to real-world psychiatric practice.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

This episode features extended Q&A sessions addressing unanswered audience questions from select presentations delivered at the 2026 NEI Spring Congress in Kissimmee, Florida:   (00:53) From Avoidance to Action: Evidence-based Pathways to Recovery for Difficult-to-Treat Anxiety by Jeffrey R. Strawn, MD, FAACAP  (15:21) Perhaps the Grass Is Greener: Why, When, and How to Switch or Combine Treatments for Schizophrenia by Christoph U. Correll, MD  (34:42) The Other Side of Motherhood: Advances in the Treatment of Postpartum Mood and Anxiety Disorders by Jennifer L. Payne, MD  Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Membership   As a valued NEI Podcast listener, Dr. Cutler's offering you 20% off new NEI Membership with code CUTLER20. Go to https://nei.global/member and join now!  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler speaks with Dr. Neill Epperson about how to evaluate cognitive complaints in women. They discuss how to differentiate between ADHD, hormonal changes (such as perimenopause), mood and anxiety disorders, and age-related cognitive decline. The conversation highlights key clinical clues, including symptom timing and fluctuation, to improve diagnostic accuracy. Practical strategies for assessment and treatment are reviewed to help clinicians make more informed, individualized decisions.   C. Neill Epperson, MD, is the Robert Freedman Endowed Professor and Chair of the Department of Psychiatry at the CU Anschutz School of Medicine. She is an internationally recognized expert in women's mental health, with research focused on the effects of hormonal transitions—such as puberty, pregnancy, and menopause—on mood, cognition, and psychiatric disorders.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler speaks with Dr. Thomas Schwartz about insomnia related to antidepressant discontinuation, including how rebound and withdrawal symptoms can emerge when tapering or stopping treatment. They review the underlying mechanisms, clinical risk factors, and how to distinguish discontinuation-related insomnia from relapse of depression or primary sleep disorders. The discussion emphasizes practical, evidence-informed strategies for safely tapering antidepressants and managing sleep disturbance in psychiatric practice.   Thomas L. Schwartz, MD, is a Distinguished Teaching Professor at Norton College of Medicine, SUNY Upstate Medical University in Syracuse, New York. He is an award-winning educator deeply involved in medical student and resident training, as well as the development of continuing medical education in psychiatry.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this episode, Dr. Andy Cutler speaks with Dr. Holly Swartz about the critical role of sleep and circadian rhythms in bipolar disorder, including how sleep disturbance can function as both a symptom and trigger of mood episodes. They discuss how clinicians can better assess sleep to identify early warning signs of relapse, along with practical strategies for intervention, including applying principles of Interpersonal and Social Rhythm Therapy (IPSRT), choosing between behavioral and pharmacologic treatments for insomnia, and avoiding sleep medications that may destabilize mood. The episode offers a clinically focused approach to improving relapse prevention through better sleep management.   Holly A. Swartz, MD, is Professor of Psychiatry at the University of Pittsburgh, Director of the Center for Advanced Psychotherapy, and Medical Director of the Depression and Manic Depression Prevention Program. An internationally recognized expert in bipolar disorder treatment, she is President of the International Society for Bipolar Disorders and known for advancing Interpersonal and Social Rhythm Therapy (IPSRT), an evidence-based approach targeting sleep, circadian rhythms, and mood stabilization to prevent relapse.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  The Social Rhythm Therapy Workbook for Bipolar Disorder  Bipolar II Disorder  Interpersonal and Social Rhythm Therapy – ipsrt.org  Depression and Bipolar Support Alliance – dbsalliance.org    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter

In this revisited episode, Dr. Robyn Thom discusses autism spectrum disorder (ASD) and the psychiatric comorbidities that frequently accompany it. She reviews how ASD is diagnosed, the core domains of social communication differences and restricted or repetitive behaviors, and why treatment often focuses on co-occurring conditions such as anxiety, ADHD, sleep disorders, and agitation. Dr. Thom also shares practical strategies for evaluating agitation, distinguishing overlapping symptoms, and selecting behavioral and pharmacologic interventions to support patients with ASD across the lifespan.  Robyn Thom, MD, is an Assistant Professor of Psychiatry at Harvard Medical School and a staff psychiatrist at the Massachusetts General Hospital Lurie Center for Autism. She specializes in treating children and adults with autism spectrum disorder and other neurodevelopmental conditions, with clinical and research interests in psychiatric comorbidities, anxiety, and mood disorders. Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter